Related Experiment Video
Updated: Feb 8, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
Published on: April 29, 2014
Apatinib treatment in extensive metastatic advanced thymic carcinoma
1Department of Radiation Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Abstract:
Apatinib is a novel oral, anti-tumor, angiogenic-targeting drug that can selectively target vascular endothelial growth factor receptor-2 (VEGFR-2). In clinical trials, this new tyrosine kinase inhibitor (TKI) has been shown to be an effective and safe treatment for a variety of malignancies. Currently, there is a lack of studies of patients with thymic carcinoma; therefore, we present a case of advanced thymic carcinoma treated with apatinib after chemotherapy failure with multiple lung metastases. This patient has been taking a dose of 500 mg of apatinib per day, and his efficacy has achieved partial response (PR), according to the RECIST 1.1 standard, and progression-free survival (PFS) is 6.3 months at this point. Apatinib will continue as his maintenance treatment. During the treatment, drug-related toxicity and side effects were tolerable. Thus, apatinib may be a meaningful option for the treatment of advanced metastatic thymic carcinoma after chemotherapy failure.
Insights
Apatinib, an anti-angiogenic drug targeting VEGFR-2, showed partial response in a patient with advanced thymic carcinoma after chemotherapy failure. This tyrosine kinase inhibitor (TKI) offers a tolerable option for metastatic disease.
Area of Science:
- Oncology
- Pharmacology
Background:
- Apatinib is an oral anti-tumor drug targeting vascular endothelial growth factor receptor-2 (VEGFR-2).
- Tyrosine kinase inhibitors (TKIs) like apatinib have demonstrated efficacy in various cancers.
- Limited research exists on apatinib's use in thymic carcinoma.
Observation:
- A patient with advanced thymic carcinoma and lung metastases was treated with apatinib after failing chemotherapy.
- The patient received 500 mg of apatinib daily.
- Treatment efficacy was assessed using RECIST 1.1 criteria.
Findings:
- Partial response (PR) was achieved.
- Progression-free survival (PFS) was 6.3 months at the time of reporting.
- Apatinib treatment was continued as maintenance therapy.
- Drug-related toxicity and side effects were tolerable.
Implications:
- Apatinib may represent a viable treatment option for advanced metastatic thymic carcinoma.
- Further investigation into apatinib for thymic carcinoma is warranted.
- This case highlights the potential of targeted therapy in refractory thymic malignancies.
More Related Videos
Related Concept Videos
Overview of Advanced Functional Groups
Functional groups are groups of atoms with specific chemical properties that occur within organic molecules and are sometimes denoted as “R”. Functional groups can “functionalize” a compound by enabling it to adopt different physical and chemical properties.
Types of Advanced Functional Groups
The table below summarizes some of the major functional groups in organic chemistry.
Extraction: Advanced Methods
Sample Preparation for Analysis: Advanced Techniques
Acid digestion with strong acids is commonly used to dissolve inorganic materials that are insoluble (do not dissolve) in water. This method can be useful for...
Cardiopulmonary Resuscitation V: Advanced Airway Management Techniques
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Treatment Resistant Cancers

